Biotech Making Great Progress

LAS VEGAS, NV / ACCESSWIRE / August 3, 2016 / In biotechnology, especially development stage, raising capital is the name of the game. As most development stage biotechs are pre­revenue, raising capital is absolutely crucial to their growth.

This is why we are so excited by the news Propanc Health Group Corporation (PPCH). PPCH, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, recently announced the Company executed a Letter Agreement with an institutional investor resulting in the Company receiving $314,286 in order to progress their lead product, PRP, towards first­in­man studies.

This capital will allow the company to commence the in­life phase of a formal 28 day toxicology study (including a toxicokinetic arm designed to determine the relationship between the level of exposure of PRP in the blood and its toxicity) according to GLP (Good Laboratory Practice) standard, method validation of an IR (infrared) dye­labelling method for analyzing the metabolism and distribution of PRP in blood plasma, as well as corporate and administrative expenses.

The Company is also presently negotiating with a contract manufacturer development and GMP (Good Manufacturing Practice) manufacture of finished drug product for PRP to be used for first­in­man studies, and expects to commence this phase of development soon.

“We continue to receive support from our lead investor, who understands the needs of our business, as we invest a significant amount of our capital into development of our lead product, PRP, towards first­in­man studies,” said James Nathanielsz, Propanc’s Chief Executive Officer. “I am pleased to say we are on track and executing our plans, which we believe could unlock significant value for the Company and its shareholders in the near future.”

The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer.

According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.

This comes shortly after an institutional investor roadshow the company went on. PPCH’s ability to continue raising capital like this will be absolutely paramount to their success.

XBiotech, Inc. (XBIT) a clinical stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases.

Shares of XBIT dropped over 32% after presenting phase 3 clinical trial results for its colon cancer drug Xilonix at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer on Saturday.

The company used an unconventional method to evaluate its cancer fighting abilities, which raised questions about any potential benefits for the drug. While their method resulted in statistically significant results, they were largely ignored due to the obscurity of the evaluation. That said, the overreaction to the downside has led to a bounce.

Anavex Life Sciences, Corp. (AVXL) is a clinical stage biopharmaceutical company which is focusing on the development of drugs/therapies for the treatment of neurodegenerative and neurodevelopmental diseases. The company’s efforts to develop its lead candidate, ANAVEX 2­73, for Alzheimer’s disease (phase II) and Rett syndrome are encouraging. In Jun 2016, the FDA’s Office of Orphan Product Development granted Orphan Drug Designation to ANAVEX 2­73 for the treatment of infantile spasms. The company also enjoys an orphan drug status for Rett syndrome in the U.S.

CytRx Corporation (CYTR) is engaged in the development and commercialization of pharmaceutical related products and services. The Zacks Consensus Estimate for its current year earnings has improved by 1.2% over the last 30 days.

Eleven Biotherapeutics, Inc. (EBIO) announced Friday that an investigational new drug application for diabetic macular edema drug EBI­031 has become effective. The drug is now effective for protein treatments for eye diseases.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 443205